Comparison · NCT02400437-7e46a4fc
MYD88 Mutated, CXCR4 Wild-type vs MYD88 Mutated, CXCR4 Mutated: Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MYD88 Mutated, CXCR4 Wild-type vs MYD88 Mutated, CXCR4 Mutated: Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status. Trial comparisons, record NCT02400437-7e46a4fc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02400437-7e46a4fc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.741 | 1 | wilson | |
| Risk in group 2 | 0.933 | 0.702 | 0.988 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0667 | -0.198 | 0.298 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.936 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on MYD88 Mutated, CXCR4 Wild-type than on MYD88 Mutated, CXCR4 Mutated | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MYD88 Mutated, CXCR4 Wild-type | Participants who were MYD88 mutated and did not have the CXCR4 mutation | 11 | 11 | OG000 |
| Group 2 | MYD88 Mutated, CXCR4 Mutated | Participants with both the MYD88 mutation and a CXCR4 mutation | 14 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status
- Description
To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or \>25% reduction in serum IgM from baseline.
- Time frame
- 2 Years
- Population
- Number of participants who achieved a response by mutational status
Source ClinicalTrials.gov
Trial
- Title
- Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
- NCT number
- NCT02400437
- Phases
- PHASE2
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- Ixazomib, Dexamethasone, Rituximab
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2020-09-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02400437?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02400437-7e46a4fc